Asia Pharmaceutical Industries

asiapharma-syria.com

ASIA Pharmaceutical Industries is one of the pioneering pharmaceutical companies in Syria and the Middle East. Within two decades, a dedicated and highly qualified team of scientists and healthcare professionals has developed a world-class company that has been awarded international quality certificates: cGMPs, ISO 9001, ISO 14001 as well as the OHSAS 18001.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TOP U.S. HEALTH OFFICIALS SELF-QUARANTINE AFTER COVID-19 CASES IN WHITE HOUSE

Fiercepharma | May 11, 2020

news image

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As many businesses in America take steps toward carefully reopening, top U.S. officials guiding the pandemic response are dealing with a COVID-19 outbreak in the country's most high-profile workplace—the White House. After a White House staffer tested positive for COVID-19, FDA Commissioner Step...

Read More

Pharma Tech

ASTRAZENECA, DAIICHI SANKYO PUSH ENHERTU CLOSER TO THE BLOCKBUSTER FRONTIER WITH STOMACH CANCER

Daiichi | January 20, 2021

news image

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

Read More

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

news image

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More

Pharmacy Market

MEDISON PHARMA ANNOUNCES EXTENSION OF MULTI-TERRITORIAL AGREEMENT WITH IMMUNOCORE AND EXPANSION INTO AUSTRALIA AND NEW ZEALAND

Medison Pharma | May 30, 2022

news image

Medison Pharma a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings plc a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. The multi-territorial agreem...

Read More
news image

TOP U.S. HEALTH OFFICIALS SELF-QUARANTINE AFTER COVID-19 CASES IN WHITE HOUSE

Fiercepharma | May 11, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. As many businesses in America take steps toward carefully reopening, top U.S. officials guiding the pandemic response are dealing with a COVID-19 outbreak in the country's most high-profile workplace—the White House. After a White House staffer tested positive for COVID-19, FDA Commissioner Step...

Read More
news image

Pharma Tech

ASTRAZENECA, DAIICHI SANKYO PUSH ENHERTU CLOSER TO THE BLOCKBUSTER FRONTIER WITH STOMACH CANCER

Daiichi | January 20, 2021

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbusterland. The FDA cleared Enhertu for HER2-positive gastric or gastroesophageal junction cancer patients who previously received Roche’s standard-of-care Herceptin, the companies said Monday. An antibody-drug conjugate, Enhertu is the first HER2-directed therapy approved in gastric cancer in a decade, the companies said. And it earned the green ...

Read More
news image

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More
news image

Pharmacy Market

MEDISON PHARMA ANNOUNCES EXTENSION OF MULTI-TERRITORIAL AGREEMENT WITH IMMUNOCORE AND EXPANSION INTO AUSTRALIA AND NEW ZEALAND

Medison Pharma | May 30, 2022

Medison Pharma a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced the addition of new markets to its multi-territorial agreement with Immunocore Holdings plc a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease. The multi-territorial agreem...

Read More